Will work together over next 60 days to try to resolve remaining issues

    TORONTO, June 13 /PRNewswire-FirstCall/ - Predictive medicine company
PreMD Inc. (TSX: PMD; Amex: PME) today announced that the Company has had
further meetings with the U.S. Food and Drug Administration (FDA) in an
effort to resolve the outstanding issues associated with obtaining broader
regulatory clearance for its non-invasive skin cholesterol test. Over the
next 60 days PreMD and the FDA will work together to try to obtain
consensus on certain conclusions from the existing clinical data in order
to develop appropriate labeling for the product.

    "The FDA has provided constructive comments and assistance in defining
the most appropriate strategy for clearance, and we look forward to a
productive outcome at the end of the 60 days," said Brent Norton, president
and CEO of PreMD.

    About PreMD Inc.

    PreMD Inc. is a leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products include a line of non-invasive
skin cholesterol tests. PreMD's other skin cholesterol products include
PREVU(x) LT, a skin cholesterol test designed for use in the life insurance
industry. The Company's cancer tests include ColorectAlert(TM),
LungAlert(TM) and a breast cancer test. PreMD's head office is located in
Toronto, Ontario and its research and product development facility is at
McMaster University in Hamilton, Ontario. For more information about PreMD,
please visit http://www.premdinc.com.

    This press release contains forward-looking statements. These
statements involve known and unknown risks and uncertainties, which could
cause the Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the successful development or marketing of the Company's products,
the competitiveness of the Company's products if successfully
commercialized, the lack of operating profit and availability of funds and
resources to pursue R&D projects, the successful and timely completion of
clinical studies, product liability, reliance on third-party manufacturers,
the ability of the Company to take advantage of business opportunities,
uncertainties related to the regulatory process, and general changes in
economic conditions. In addition, while the Company routinely obtains
patents for its products and technology, the protection offered by the
Company's patents and patent applications may be challenged, invalidated or
circumvented by our competitors and there can be no guarantee of our
ability to obtain or maintain patent protection for our products or product
candidates.

    Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned not to rely on these forward-looking
statements. PreMD is providing this information as of the date of this
press release and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of
new information, future events or otherwise.

Link to this page: